Comparison
Both peptides stimulate growth hormone secretion but act through entirely different receptors — ipamorelin mimics ghrelin while sermorelin mimics GHRH — producing distinct GH pulse patterns and research profiles.
| Attribute | Ipamorelin | Sermorelin |
|---|---|---|
| Full name | Ipamorelin | Sermorelin (GHRH 1-29) |
| Class | GHRP — growth hormone releasing peptide (ghrelin receptor agonist) | GHRH analogue — first 29 amino acids of endogenous GHRH |
| Mechanism | Binds ghrelin receptor (GHS-R1a) → pituitary GH release; does NOT suppress somatostatin | Binds GHRH receptor on pituitary somatotrophs → amplifies pulsatile GH secretion; somatostatin can attenuate effect |
| Half-life | ~2 hours | ~10–20 minutes |
| Commonly reported doses | Commonly reported doses range from 100 to 300 mcg per injection, 1–3× daily | Commonly reported doses range from 100 to 300 mcg per injection, once nightly (most common) or 2–3× daily |
| Routes | SubQ injection | SubQ injection |
| Primary reported use | GH pulse stimulation, sleep quality, body composition, anti-aging research | GH axis support, anti-aging, body composition, hormone optimisation research |
Receptor mechanism. Ipamorelin acts on the ghrelin receptor (GHS-R1a), a pathway entirely distinct from the GHRH receptor that sermorelin targets. This mechanistic separation is pharmacologically significant: because the two peptides operate at different receptor sites, they can be co-administered without competition — and their combination produces a synergistic GH pulse that is greater than either agent alone. The pairing of a GHRP with a GHRH analogue is among the most commonly reported stacks in GH axis research.
Selectivity. Ipamorelin is noted in research for its hormonal selectivity: research has investigated ipamorelin for its potential role in stimulating GH without meaningfully increasing cortisol, prolactin, or ACTH at research doses — a profile not shared by older GHRPs such as GHRP-2 or GHRP-6, which can produce notable cortisol and prolactin elevations. Sermorelin, by contrast, is physiological in its action, essentially delivering a signal chemically identical to the body's own GHRH, making it a close mimic of the endogenous pulsatile drive.
Somatostatin sensitivity. Sermorelin's effectiveness is partially gated by somatostatin — the GH-inhibiting peptide that rises during the day and attenuates GHRH-driven GH release. Timing injections to coincide with periods of low somatostatin tone (most commonly during sleep onset on an empty stomach) is a factor commonly factored into sermorelin protocols. Ipamorelin operates through the ghrelin receptor pathway and is comparatively less sensitive to somatostatin interference, giving it somewhat more flexibility in injection timing.
Sermorelin is a synthetic analogue comprising the first 29 amino acids of endogenous growth hormone-releasing hormone (GHRH 1-44). It binds the GHRH receptor (GHRHR) on pituitary somatotroph cells and activates adenylyl cyclase via G-protein coupling, increasing intracellular cAMP and driving GH synthesis and release. The result is an amplification of the body's own pulsatile GH pattern rather than a novel pulse imposed from outside.
Ipamorelin is a pentapeptide that acts as a selective agonist at the growth hormone secretagogue receptor type 1a (GHS-R1a), more commonly called the ghrelin receptor. Binding at this receptor triggers a separate intracellular cascade (IP3/DAG signalling) that also culminates in pituitary GH release, but via a mechanistically distinct route. This separate pathway is the basis for complementarity when the two compounds are co-administered.
When used together, sermorelin drives the GHRHR pathway while ipamorelin drives the GHS-R1a pathway simultaneously. Research has investigated this dual-receptor activation for its potential role in producing supra-additive GH pulses, and anecdotal reports suggest this combination is among the most effective GHRP/GHRH pairings for GH axis stimulation.
Both peptides share a broad overlap in reported research applications: GH axis support, body composition (lean mass accrual, adipose reduction), exercise recovery, and anti-aging research contexts are documented for each.
Ipamorelin has received specific attention in sleep quality research — research has investigated ipamorelin for its potential role in deepening slow-wave (stage 3) sleep, the phase during which endogenous GH secretion is normally highest. Anecdotal reports suggest improvement in sleep architecture is among the most consistently noted subjective effects.
Sermorelin has a longer clinical research history and has been investigated in paediatric growth hormone deficiency contexts, where stimulating endogenous GH secretion rather than replacing GH exogenously was the research objective. This background gives sermorelin a somewhat more established literature than many newer peptides.
Ipamorelin: Commonly reported doses range from 100 to 300 mcg per injection, administered 1–3 times daily. A first dose at or near bedtime is a commonly reported protocol, capitalising on the overlap with the natural nocturnal GH pulse. Additional doses are often reported at waking or pre-workout when multiple daily injections are used.
Sermorelin: The most widely reported protocol involves a single nightly injection of 100–300 mcg administered approximately 30 minutes before sleep on an empty stomach, to minimise somatostatin interference and coincide with the early nocturnal GH surge. Some researchers report 2–3 daily injections, though the nightly single-dose approach is most frequently cited in the literature and in anecdotal accounts.
Both ipamorelin and sermorelin are administered by subcutaneous injection, typically using insulin syringes (U-100 or U-29 gauge). Ipamorelin is occasionally reported via intramuscular injection in some research protocols. Both peptides are reconstituted from lyophilised powder using bacteriostatic water and stored refrigerated after reconstitution. Neither compound is orally bioavailable in its peptide form.
Reported side effects in research and anecdotal accounts include the following for both peptides: transient water retention (particularly in the early weeks), tingling or numbness in the extremities (carpal tunnel-like), fatigue, and increased hunger. These effects are generally associated with elevated GH and downstream IGF-1 and are reported to be dose-dependent.
Ipamorelin specifically: Research consistently highlights ipamorelin's minimal impact on cortisol and prolactin as a distinguishing feature compared to older GHRPs. Reported side effects in research and anecdotal accounts specific to ipamorelin are generally limited to the class-wide GH effects noted above.
Sermorelin specifically: Injection site redness, swelling, or discomfort is more commonly reported with sermorelin than with ipamorelin, and is among the most frequently cited adverse effects in clinical documentation. Flushing and headache have also been reported in research and anecdotal accounts.
Ipamorelin tends to be preferred in research contexts where minimising off-target hormonal impact is a priority — particularly where elevated cortisol would be undesirable. Its longer half-life relative to sermorelin also offers slightly more flexible injection timing.
Sermorelin tends to be preferred where physiological fidelity is the research objective — specifically, where mimicking the body's own GHRH signal (rather than introducing a ghrelin-receptor agonist) is considered important. Both are widely used together, and the combination is frequently considered the more complete GH axis stimulus.
Yes. Ipamorelin and sermorelin can be co-administered and are frequently reported together in both research literature and anecdotal accounts. Because they act on distinct receptor systems — the ghrelin receptor (GHS-R1a) and the GHRH receptor respectively — there is no mechanistic competition between them. Their combination produces a synergistic GH pulse that research has investigated as being greater in magnitude than either compound alone.
This GHRP/GHRH combination approach is one of the most researched GH axis stacks in the peptide research field. The two injections are commonly reported to be administered simultaneously or within a short window of each other, typically at the preferred dosing time for the protocol in use.
Note that ipamorelin is also frequently combined with CJC-1295 — another GHRH analogue with a significantly longer half-life than sermorelin. For a detailed comparison of those two compounds, see the Ipamorelin vs CJC-1295 comparison.
Researchers commonly select ipamorelin when specificity and low off-target hormonal impact are research priorities — particularly its selectivity for GH over cortisol and prolactin, which distinguishes it within the GHRP class.
Researchers commonly select sermorelin when mimicking endogenous GHRH physiology is the specific research objective — its mechanism is a direct replication of the body's own GH-stimulating signal, and it carries a more established clinical research history than many synthetic GH secretagogues.
In practice, both compounds are frequently co-administered to leverage complementary receptor pathways. The combination represents a comprehensive GH axis stimulus and is among the most widely reported GHRP/GHRH pairings in research and anecdotal contexts alike.
Is ipamorelin stronger than sermorelin?
A direct potency comparison is not straightforward because the two compounds act through entirely different receptor pathways. Ipamorelin typically produces a more discrete, acute GH pulse via the ghrelin receptor. Sermorelin amplifies the body's own pulsatile GH pattern via the GHRH receptor, producing a response more physiological in character. Research has not established a clean potency hierarchy — the more relevant consideration is the mechanistic distinction and the complementarity when both are used together.
Can ipamorelin and sermorelin be combined?
Yes. Co-administration is commonly reported and is mechanistically well-supported: because ipamorelin binds the ghrelin receptor (GHS-R1a) and sermorelin binds the GHRH receptor (GHRHR), the two compounds act on separate systems and produce complementary rather than redundant effects. Research has investigated this combination for its potential role in generating a synergistic GH pulse greater than either compound alone, and it remains one of the most frequently cited GHRP/GHRH pairings in the field.
Does sermorelin have a profile page on WikiPeptide?
Yes. The full sermorelin research reference — covering mechanism, commonly reported protocol, synergy with GHRPs, comparison to CJC-1295, and storage — is available at the Sermorelin Peptide Profile.
For goal-oriented research context, see the muscle growth and longevity goal pages, which cross-reference both ipamorelin and sermorelin alongside other relevant compounds.
Compound Profiles